← Leaderboards
Kristen M Pogreba-Brown
University Of Arizona
$1,941,525
Attributed
$1,941,525
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $657.2K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,941,525 · 1
By mechanism
R01$1,941,525 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Arizona
Same institution · by research overlap
- Douglas L. Taren$89,961
- Marlys Hearst Witte$12,039,762
Others in their field
Other Rising Stars on “Disorders Of Gut-Brain Interaction”
- Jacob Matthew Allen · University Of Illinois At Urbana-Champaign$2,622,833
- Andrei A Vakhtin · Lovelace Biomedical Research Institute$2,171,443
- Roberta Sclocco · Spaulding Rehabilitation Hospital$2,119,090
- Santiago Cuesta · Rutgers, The State Univ Of N.J.$1,391,376
- Susanne Brummelte · Wayne State University$1,336,903
- Hugo Fernando Posada-Quintero · University Of Connecticut Storrs$1,292,215
Research focus
Disorders Of Gut-Brain Interaction2019-NcovAcuteDisease ProgressionAffectAmericanArizonaAcute InfectionAdultBiologicalBiological MarkersBlood SpecimenCaregiversChronicCohortComorbidityAssociated SymptomCovid-19 PatientCritical PathwaysBacterial InfectionsDiagnosisDiagnosticDiarrheaEnrollment
Grant awards (3)
Determining the Incidence, Risk Factors and Biological Drivers of Irritable Bowel Syndrome (IBS) as Part of the Constellation of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Outcomes$657,203
R01 · FY2025 · DK · contact PI
Determining the Incidence, Risk Factors and Biological Drivers of Irritable Bowel Syndrome (IBS) as Part of the Constellation of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Outcomes$634,144
R01 · FY2024 · DK · contact PI
Determining the Incidence, Risk Factors and Biological Drivers of Irritable Bowel Syndrome (IBS) as Part of the Constellation of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Outcomes$650,178
R01 · FY2023 · DK · contact PI